BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) is a special purpose acquisition company operating in the oncology and biopharmaceutical sector. The company filed an 8-K with the Securities and Exchange Commission on June 22, 2026, under accession number 0001193125-26-277513, disclosing a material corporate event to investors on a current basis. HLXB targets therapeutics focused on cancer treatment, reflecting continued SPAC activity in the life sciences and clinical-stage oncology space. Sponsor details and the precise IPO vintage are subject to ongoing verification in SpacDesk's data pipeline. For the full filing history, sponsor profile, and deal timeline for HLXB, sign up for complete access at SpacDesk.